Abivax SA, of Paris, said Bpifrance approved €36 million (USS$39.1 million) in nondilutive funding (a €20.1 million grant, and a €15.9 million loan refundable upon success) to support its phase IIb/III trial of ABX-464 in high-risk patients with COVID-19 as well as manufacturing scale-up and additional clinical and other development costs.
Apeiron Biologics AG, of Vienna, said it will complete a capital increase to support the further development of APN-01 for the treatment of severely ill COVID-19 patients as well as the development of immuno-oncology projects. The Vienna Insurance Group will lead the financing round and secures the private placement as an anchor investor. Investment commitments from existing shareholders and new institutional and private international investors have been provided. APN-01 specifically targets the coronavirus by imitating the receptor ACE2.
Greenlight Biosciences Inc., of Boston, said it closed an oversubscribed $17 million special purpose funding round from new and existing investors to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine. In addition to expanding its manufacturing capacity, the company is developing several differentiated mRNA vaccine candidates against SARS-CoV2.
Hemogenyx Pharmaceuticals plc, of London, U.K., said it raised £2.5 million (US$3.05 million) through an oversubscribed placing of 35.71 million ordinary shares at 7 pence each. The funding is conditional on shareholders approving the special resolution to be proposed at the company's annual general meeting June 4. The funds will be used to advance the company’s humanized mice for the potential development of human neutralizing antibodies to be used against COVID-19 and related COVID-19 work; to advance IND-enabling studies for HEMO-CAR-T, which is being developed as a potential blood cancer treatment; and for general working capital purposes.
Modulus Discovery Inc., of Tokyo, said it closed its series B funding round for ¥2.71 billion (US$$25.5 million) and will use the proceeds to advance its small-molecule lead programs in oncology and inflammatory/immune disorders and expand its portfolio of early programs and collaborations, including those with its strategic partner Peptidream Inc., of Kanagawa, Japan.
Travecta Therapeutics Pte. Ltd., of Singapore, secured $15 million in series A financing to support development of TVT-004, its lead non-opioid product targeting pain. The candidate, based on discoveries at the Duke-NUS Medical School, is a small molecule conjugated with the company's blood brain-barrier transport platform delivery technology, which uses the Mfsd2a lysolipid transport system. The financing was led by TKS1, a life science-focused venture capital fund formed by the partnership between Sprim and Tikehau Capital.